Peptides for Women Episode 7: Three Benefits of GLP-1s that Aren't Weight Loss
Welcome back to Peptides for Women podcast!
In today's episode, we’re talking about three major benefits you can get from using a GLP-1s beyond weight loss. You’ll see that GLP-1s can help regulate your blood sugar, calm inflammation, and support your liver so you feel better day-to-day.
BENEFIT #1: Better Glucose & Insulin Regulation
- How GLP-1s slow gastric emptying, which means steadier blood sugar after meals
- The impact on insulin sensitivity and long-term metabolic health
BENEFIT #2: Lower Inflammation
- My personal story: how tirzepatide helped relieve my hip pain and plantar fasciitis
- What the research is showing about inflammation markers improving on GLP-1 therapy
BENEFIT #3: Improved Liver Health
- How GLP-1s can lower liver enzymes like ALT, AST, and GGT
- The link between fatty liver, perimenopause, and insulin resistance
- What early research says about GLP-1s as a potential therapy for NAFLD (non-alcoholic fatty liver disease)
🔗 Resources:
1. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial — https://pubmed.ncbi.nlm.nih.gov/28526920/
2. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program — https://pubmed.ncbi.nlm.nih.gov/35724304/
3. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes — https://pubmed.ncbi.nlm.nih.gov/37874653/
4. Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials — https://pubmed.ncbi.nlm.nih.gov/36056351/
5. Effects of once-weekly semaglutide 2.4 mg on C-reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): Exploratory analyses of three randomised, double-blind, placebo-controlled, phase 3 trials — https://pubmed.ncbi.nlm.nih.gov/36467859/
6. GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-κB signalling pathway — https://pubmed.ncbi.nlm.nih.gov/33641439/
7. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis — https://pubmed.ncbi.nlm.nih.gov/33185364/
8. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study — https://pubmed.ncbi.nlm.nih.gov/26608256/
9. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis — https://pubmed.ncbi.nlm.nih.gov/38856224/
Links & Resources:
- 🔗 Learn more or order peptides at: elliemd.com/JenniferWoodwardNutrition
- 🎯 Take the Peptides Quiz to find out what may work for your body: https://connect.jenniferwoodwardnutrition.com/widget/form/CoNzXJkbFdCpgo1hWPTN
- Enroll in the Peptides for Practitioners Certification Course and get $100 off for podcast subscribers: https://www.carrotsncake.com/offers/TrVo7mCz?coupon_code=PFPJENNIFER
- 🧬 Want to pair GLP-1s with functional lab testing? https://learn.jenniferwoodwardnutrition.com/invitation
- 📩 Grab The Body Edit Guide here for full protocols, dosing, labs, and more: https://stan.store/jenniferwoodwardnutrition/p/get-the-body-edit
‼️Disclaimer‼️
This podcast is for informational purposes only and does not provide medical advice. Always speak with your licensed healthcare provider before starting or changing any medication or treatment plan.